Miraculins develops new assay in preeclampsia program

Miraculins (TSX-V:MOM) has developed an ultrasensitive assay for the detection of soluble endoglin, optimized for serum and urine, in an ELISA format as part of its preeclampsia program.  Endoglin is the lead biomarker in its preeclampsia portfolio.

“Our initial focus will be to offer this assay to investigators as a research-use-only kit to support preeclampsia research, preeclampsia therapy development and clinical trials,” CEO Christopher Moreau said in a statement.  “However, we will also be looking at the potential of entering the analyte specific reagent (ASR) market in the U.S., using clinical grade endoglin antibodies.”

Dr. Stephen Frost, director of R&D for Miraculins, said the assay as the ability to detect extremely low levels of endoglin in urine.  “This format could unlock new opportunities for creating a non-invasive test for preeclampsia by testing urine samples that are already routinely provided by women during their regular doctor’s visits throughout pregnancy,” he added.